Iridex Reports First Quarter 2026 Financial Results

Iridex Corporation reported its financial results for Q1 2026, showing total revenue of $11.8 million, a 1% decline from the previous year, largely due to decreased sales in retina systems. The company’s U.S. glaucoma business saw growth, particularly with the Cyclo G6 product family. Gross profit was $4.7 million with a gross margin of 40%. Despite a net loss of $0.5 million, the company remains optimistic about achieving positive cash flow for the year, reaffirming annual revenue guidance of $51-$53 million amidst market challenges.